Extracorporeal membrane oxygenation and severe acute respiratory distress secondary to legionella: 10 year experience

ASAIO Journal

Volumn 59, Issue 3, 2013, Pages 328-330

  Noah, Moronke A ^a   Ramachandra, Geethanjali ^a   Hickey, Margaret M ^a   Jenkins, David R ^a   Harvey, Chris J ^a   Westrope, Claire A ^a   Firmin, Richard K ^a   Peek, Giles J ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

extracorporeal membrane oxygenation; Legionella; Legionnaire's disease; severe respiratory failure

Indexed keywords

EXTRACORPOREAL MEMBRANE OXYGENATION; GAS EXCHANGE; HOSPITAL DISCHARGE; INTENSIVE CARE; LEGIONELLA; LEGIONNAIRE'S DISEASE; PULMONARY FUNCTION; RESPIRATORY FAILURE;

BIOMATERIALS; BIOPHYSICS;

RESPIRATORY THERAPY;

CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TEICOPLANIN;

ADULT; CLINICAL ARTICLE; EXTRACORPOREAL OXYGENATION; FEMALE; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE; LEGIONELLA; MALE; PNEUMONIA; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REVIEW;

ADULT; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HUMANS; LEGIONELLA; LEGIONELLOSIS; MALE; MIDDLE AGED; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84877731730     PISSN: 10582916     EISSN: 1538943X     Source Type: Journal    
DOI: 10.1097/MAT.0b013e31829119c6     Document Type: Review

References (10)

1. Health Protection Agency: Legionnaire's disease in residents of England and Wales-Cases and deaths by sex, 1980-2009. Available at: http://www.hpa.org. uk/web/HPAweb&HPAwebStandard/HPAweb-C/1195733778196. Accessed June 8, 2012.
2. Manzor O, Majithia D, Saravolatz L: In vitro activities of seven quinolones and two macrolides against Legionella isolates. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 39: 273, 1999.
3. Sabrià M, Pedro-Botet ML, Gómez J, et al; Legionnaires Disease Therapy Group: Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 128: 1401-1405, 2005.
4. el-Ebiary M, Sarmiento X, Torres A, et al: Prognostic factors of severe Legionella pneumonia requiring admission to ICU. Am J Respir Crit Care Med 156: 1467-1472, 1997.
5. Gacouin A, Le Tulzo Y, Lavoue S, et al: Severe pneumonia due to Legionella pneumophila: Prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med 28: 686-691, 2002.
6. Peek GJ, Mugford M, Tiruvoipati R, et al; CESAR Trial Collaboration: Effcacy and economic assessment of conventional ventila-tory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomised controlled trial. Lancet 374: 1351-1363, 2009.
7. Noah MA, Peek GJ, Finney SJ, et al: Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 infuenza A(H1N1). JAMA 306: 1659-1668, 2011.
8. Ichiba S, Jenkins DR, Peek GJ, et al: Severe acute respiratory failure due to Legionella pneumonia treated with extracorporeal membrane oxygenation. Clin Infect Dis 28: 686-687, 1999.
9. Neil K, Berkelman R: Increasing incidence of legionellosis in the United States, 1990-2005: Changing epidemiologic trends. Clin Infect Dis 47: 591-599, 2008.
10. Rello J, Bodi M, Mariscal D, et al: Microbiological testing and outcomes of patients with severe community acquired pneumonia. Chest 123: 174-180, 2003.